FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3137053114> ?p ?o ?g. }

• W3137053114 endingPage "160" @default.
• W3137053114 startingPage "156" @default.
• W3137053114 abstract "Treatment guidelines for chronic hepatitis B (CHB) do not recommend antiviral therapy for patients in the immune-tolerant phase of the disease, which generally occurs in children who acquire hepatitis B virus (HBV) vertically and may last for decades. On the basis of promising results of a pilot study, we conducted a randomized, controlled, multicenter study to evaluate the efficacy and safety of antiviral therapy in children and adolescents with immune-tolerant CHB.Fifty-nine children aged 3 to <18 years hepatitis B e antigen-positive with an HBV DNA titer >20,000 IU/mL and persistently normal alanine aminotransferase levels were randomized to 56 weeks of antiviral therapy with an oral nucleoside analogue [entecavir or lamivudine], combined with subcutaneous peginterferon alfa-2a from week 8, or 80 weeks of untreated observation. The primary efficacy outcome was hepatitis B surface antigen loss 24 weeks post-treatment in the antiviral therapy group or at the end of observation in the control group.Enrollment was terminated after the results of two similar studies showed that similar antiviral regimens were ineffective in children and adults with immune-tolerant CHB. At 24 weeks post-treatment, 1 of 26 patients in the antiviral treatment group experienced HBsAg loss (vs none of 33 patients in the control group). No serious treatment-related adverse events were reported, and no patients discontinued treatment because of adverse events.The antiviral regimen evaluated in this trial had an acceptable tolerability profile, but was ineffective in children and adolescents with immune-tolerant CHB." @default.
• W3137053114 created "2021-03-29" @default.
• W3137053114 creator A5001162342 @default.
• W3137053114 creator A5006405927 @default.
• W3137053114 creator A5019690978 @default.
• W3137053114 creator A5025413690 @default.
• W3137053114 creator A5038656678 @default.
• W3137053114 creator A5046470723 @default.
• W3137053114 creator A5068523462 @default.
• W3137053114 creator A5075862876 @default.
• W3137053114 creator A5077257085 @default.
• W3137053114 creator A5079804465 @default.
• W3137053114 date "2021-03-03" @default.
• W3137053114 modified "2023-10-18" @default.
• W3137053114 title "Peginterferon Alfa-2a (40KD) Plus Lamivudine or Entecavir in Children With Immune-Tolerant Chronic Hepatitis B" @default.
• W3137053114 cites W1969776963 @default.
• W3137053114 cites W1975056120 @default.
• W3137053114 cites W1991892150 @default.
• W3137053114 cites W1996263738 @default.
• W3137053114 cites W2032153894 @default.
• W3137053114 cites W2041824372 @default.
• W3137053114 cites W2056280345 @default.
• W3137053114 cites W2068957651 @default.
• W3137053114 cites W2092995058 @default.
• W3137053114 cites W2122899893 @default.
• W3137053114 cites W2173698250 @default.
• W3137053114 cites W2328080548 @default.
• W3137053114 cites W2523033169 @default.
• W3137053114 cites W2605785536 @default.
• W3137053114 cites W2610539512 @default.
• W3137053114 cites W2896700797 @default.
• W3137053114 cites W2905371854 @default.
• W3137053114 doi "https://doi.org/10.1097/mpg.0000000000003118" @default.
• W3137053114 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33720089" @default.
• W3137053114 hasPublicationYear "2021" @default.
• W3137053114 type Work @default.
• W3137053114 sameAs 3137053114 @default.
• W3137053114 citedByCount "7" @default.
• W3137053114 countsByYear W31370531142022 @default.
• W3137053114 countsByYear W31370531142023 @default.
• W3137053114 crossrefType "journal-article" @default.
• W3137053114 hasAuthorship W3137053114A5001162342 @default.
• W3137053114 hasAuthorship W3137053114A5006405927 @default.
• W3137053114 hasAuthorship W3137053114A5019690978 @default.
• W3137053114 hasAuthorship W3137053114A5025413690 @default.
• W3137053114 hasAuthorship W3137053114A5038656678 @default.
• W3137053114 hasAuthorship W3137053114A5046470723 @default.
• W3137053114 hasAuthorship W3137053114A5068523462 @default.
• W3137053114 hasAuthorship W3137053114A5075862876 @default.
• W3137053114 hasAuthorship W3137053114A5077257085 @default.
• W3137053114 hasAuthorship W3137053114A5079804465 @default.
• W3137053114 hasConcept C126322002 @default.
• W3137053114 hasConcept C185592680 @default.
• W3137053114 hasConcept C197934379 @default.
• W3137053114 hasConcept C203014093 @default.
• W3137053114 hasConcept C2522874641 @default.
• W3137053114 hasConcept C2775940106 @default.
• W3137053114 hasConcept C2776175608 @default.
• W3137053114 hasConcept C2776543447 @default.
• W3137053114 hasConcept C2777333352 @default.
• W3137053114 hasConcept C2777382497 @default.
• W3137053114 hasConcept C2777410769 @default.
• W3137053114 hasConcept C2777869810 @default.
• W3137053114 hasConcept C2778375690 @default.
• W3137053114 hasConcept C2779517838 @default.
• W3137053114 hasConcept C2780593183 @default.
• W3137053114 hasConcept C2781413609 @default.
• W3137053114 hasConcept C71240020 @default.
• W3137053114 hasConcept C71924100 @default.
• W3137053114 hasConcept C90924648 @default.
• W3137053114 hasConceptScore W3137053114C126322002 @default.
• W3137053114 hasConceptScore W3137053114C185592680 @default.
• W3137053114 hasConceptScore W3137053114C197934379 @default.
• W3137053114 hasConceptScore W3137053114C203014093 @default.
• W3137053114 hasConceptScore W3137053114C2522874641 @default.
• W3137053114 hasConceptScore W3137053114C2775940106 @default.
• W3137053114 hasConceptScore W3137053114C2776175608 @default.
• W3137053114 hasConceptScore W3137053114C2776543447 @default.
• W3137053114 hasConceptScore W3137053114C2777333352 @default.
• W3137053114 hasConceptScore W3137053114C2777382497 @default.
• W3137053114 hasConceptScore W3137053114C2777410769 @default.
• W3137053114 hasConceptScore W3137053114C2777869810 @default.
• W3137053114 hasConceptScore W3137053114C2778375690 @default.
• W3137053114 hasConceptScore W3137053114C2779517838 @default.
• W3137053114 hasConceptScore W3137053114C2780593183 @default.
• W3137053114 hasConceptScore W3137053114C2781413609 @default.
• W3137053114 hasConceptScore W3137053114C71240020 @default.
• W3137053114 hasConceptScore W3137053114C71924100 @default.
• W3137053114 hasConceptScore W3137053114C90924648 @default.
• W3137053114 hasIssue "2" @default.
• W3137053114 hasLocation W31370531141 @default.
• W3137053114 hasLocation W31370531142 @default.
• W3137053114 hasOpenAccess W3137053114 @default.
• W3137053114 hasPrimaryLocation W31370531141 @default.
• W3137053114 hasRelatedWork W1499677049 @default.
• W3137053114 hasRelatedWork W2153078062 @default.
• W3137053114 hasRelatedWork W2379804742 @default.
• W3137053114 hasRelatedWork W2392261344 @default.

• next